Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(3.92)
# 656
Out of 5,033 analysts
53
Total ratings
40%
Success rate
17.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Assumes: Overweight | n/a | $9.22 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $86.95 | +1.21% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $20.99 | - | 3 | Sep 8, 2025 | |
| LEGN Legend Biotech | Assumes: Overweight | $55 → $66 | $31.96 | +106.51% | 1 | Aug 27, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $27.94 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $47.89 | +100.46% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $9.92 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $101.52 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.87 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.49 | - | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $18.25 | -28.71% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.08 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $69.15 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $87.57 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $42.33 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.03 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.56 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $143.00 | +104.20% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $416.81 | -11.23% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.77 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.48 | - | 1 | May 30, 2017 |
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $9.22
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $86.95
Upside: +1.21%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.99
Upside: -
Legend Biotech
Aug 27, 2025
Assumes: Overweight
Price Target: $55 → $66
Current: $31.96
Upside: +106.51%
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $27.94
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $47.89
Upside: +100.46%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.92
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $101.52
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.87
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.49
Upside: -
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $18.25
Upside: -28.71%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.08
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $69.15
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $87.57
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $42.33
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.03
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.56
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $143.00
Upside: +104.20%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $416.81
Upside: -11.23%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.77
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.48
Upside: -